MX2007015848A - Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2. - Google Patents

Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2.

Info

Publication number
MX2007015848A
MX2007015848A MX2007015848A MX2007015848A MX2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A
Authority
MX
Mexico
Prior art keywords
type
risk
diabetes mellitus
genetic variants
diagnostic markers
Prior art date
Application number
MX2007015848A
Other languages
English (en)
Inventor
Struan F A Grant
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of MX2007015848A publication Critical patent/MX2007015848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Los polimorfismos en el gen TCF7L2 son mostrados por el analisis de asociacion como un gen de susceptibilidad para la diabetes tipo II. Se describen los metodos de diagnostico de la susceptibilidad a la diabetes, de susceptibilidad disminuida a la diabetes y de proteccion contra diabetes, asi como los metodos de tratamiento para la diabetes tipo II.
MX2007015848A 2005-06-20 2006-06-16 Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2. MX2007015848A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69217405P 2005-06-20 2005-06-20
US75715506P 2006-01-06 2006-01-06
PCT/IS2006/000014 WO2006137085A1 (en) 2005-06-20 2006-06-16 Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2007015848A true MX2007015848A (es) 2008-04-22

Family

ID=37036993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015848A MX2007015848A (es) 2005-06-20 2006-06-16 Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2.

Country Status (15)

Country Link
US (3) US7585630B2 (es)
EP (1) EP1907569B1 (es)
JP (1) JP5301987B2 (es)
KR (1) KR101374304B1 (es)
CN (1) CN101238222B (es)
AU (1) AU2006260477B2 (es)
BR (1) BRPI0612301A2 (es)
CA (1) CA2612475C (es)
EA (1) EA016397B1 (es)
HK (1) HK1117569A1 (es)
IL (1) IL188147A (es)
MX (1) MX2007015848A (es)
NO (1) NO341910B1 (es)
NZ (1) NZ564285A (es)
WO (1) WO2006137085A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
NZ564285A (en) * 2005-06-20 2010-03-26 Decode Genetics Ehf Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AU2007326838B9 (en) * 2006-11-30 2014-02-13 Decode Genetics Ehf. Genetic susceptibility variants of Type 2 diabetes mellitus
EP2057183A2 (en) * 2007-03-01 2009-05-13 Novetide Ltd. High purity peptides
US20100184839A1 (en) * 2007-04-30 2010-07-22 Avishay Vaknin Allelic polymorphism associated with diabetes
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ598009A (en) 2009-07-10 2013-11-29 Decode Genetics Ehf Genetic markers associated with risk of diabetes mellitus
EP3646859A1 (en) * 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
BR112012032579B1 (pt) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
HUE043540T2 (hu) 2011-07-15 2019-08-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2906695A1 (en) * 2013-03-14 2014-09-25 The Children's Hospital Of Philadelphia Tcf7l2 variant and methods of use thereof in diagnostic and drug screening assays
RU2521202C1 (ru) * 2013-04-12 2014-06-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Способ прогнозирования риска развития сахарного диабета второго типа у больных гипертонической болезнью
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN103882127B (zh) * 2014-03-13 2016-03-16 河北联合大学 用于预测患2型糖尿病肾病发生风险的试剂盒
WO2016201438A1 (en) * 2015-06-11 2016-12-15 The Children's Hospital Of Philadelphia New targets modulated by a casual variant of type 2 diabetes (t2d) embedded within the tcf7l2 gene and methods of use thereof for identifying agents having efficacy for the treatment of type 2 diabetes and other metabolic disorders
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
CN109182508A (zh) * 2018-10-22 2019-01-11 北京华夏时代生物工程有限公司 Tcf7l2基因单核苷酸多态性的荧光原位杂交测序方法
TWI702292B (zh) * 2018-12-28 2020-08-21 薩摩亞商康多富國際有限公司 個人化新陳代謝疾病保健食品組合的決定方法及非暫態電腦可讀取儲存媒體

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3486467T3 (de) * 1983-01-10 2004-10-14 Gen-Probe Inc., San Diego Verfahren zum Nachweis, Identifizieren und Quantifizieren von Organismen und Viren
US5288611A (en) * 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3534934A1 (de) * 1985-10-01 1987-04-02 Draegerwerk Ag Kolorimetrisches gasdosimeter
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
DE69919707T2 (de) * 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US6512102B1 (en) * 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
ES2296667T3 (es) * 1999-12-17 2008-05-01 Novartis Vaccines And Diagnostics, Inc. Inhibidores basados en pirazina de glicogeno sintasa quinasa-3.
ES2246927T3 (es) * 1999-12-17 2006-03-01 Chiron Corporation Inhibidores biciclicos de glucogeno sintasa quinasa 3.
CN1276974C (zh) * 2000-07-27 2006-09-27 希龙公司 Gsk3多肽
AU785425B2 (en) * 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
WO2003004488A1 (en) * 2001-07-03 2003-01-16 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
EP1423535A4 (en) * 2001-08-04 2005-07-06 Whitehead Biomedical Inst HAPLOTYP CARD OF THE HUMAN GENOME AND USES THEREOF
WO2003024447A1 (en) 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6762185B1 (en) * 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
WO2004018419A2 (en) * 2002-08-23 2004-03-04 Chiron Corporation Benzimidazole quinolinones and uses thereof
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
AU2003290562A1 (en) * 2002-11-01 2004-06-07 Decode Genetics Ehf. HUMAN TYPE II DIABETES GENE-SLIT-3 LOCATED ON CHROMOSOME 5q35
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits
CN1548553A (zh) * 2003-05-21 2004-11-24 中国医学科学院基础医学研究所 用于预测2型糖尿病易感性的试剂盒及引物
US6991110B2 (en) * 2003-07-02 2006-01-31 Inficon, Inc. Package for storing sensor crystals and related method of use
WO2005021025A2 (en) * 2003-08-28 2005-03-10 Choongwae Pharma Corporation MODULATION OF β-CATENIN/TCF ACTIVATED TRANSCRIPTION
NZ564285A (en) * 2005-06-20 2010-03-26 Decode Genetics Ehf Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus

Also Published As

Publication number Publication date
EA016397B1 (ru) 2012-04-30
IL188147A (en) 2013-02-28
JP2008546403A (ja) 2008-12-25
CA2612475C (en) 2015-07-28
EP1907569B1 (en) 2013-04-10
AU2006260477B2 (en) 2012-02-23
EP1907569A1 (en) 2008-04-09
KR20080051128A (ko) 2008-06-10
JP5301987B2 (ja) 2013-09-25
NO341910B1 (no) 2018-02-19
KR101374304B1 (ko) 2014-03-14
CN101238222A (zh) 2008-08-06
US20120149016A1 (en) 2012-06-14
NZ564285A (en) 2010-03-26
CA2612475A1 (en) 2006-12-28
HK1117569A1 (en) 2009-01-16
AU2006260477A1 (en) 2006-12-28
CN101238222B (zh) 2013-04-10
IL188147A0 (en) 2008-03-20
US20090275043A1 (en) 2009-11-05
NO20080389L (no) 2008-01-21
US20060286588A1 (en) 2006-12-21
WO2006137085A1 (en) 2006-12-28
EA200800087A1 (ru) 2008-06-30
AU2006260477A8 (en) 2006-12-28
BRPI0612301A2 (pt) 2009-01-27
US7585630B2 (en) 2009-09-08

Similar Documents

Publication Publication Date Title
HK1117569A1 (en) Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus
IL249715B (en) N-butyl-deoxynojirimycin for use as a drug for the treatment of Pompe disease in combination with an enzyme replacement therapy agent
EP1904630A4 (en) METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
IL225203A (en) An isolated complementary factor polypeptide, methods for its preparation, its uses and a factor that lowers its expression or activity
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
MY153198A (en) Inhibitors of protein aggregation
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2008103470A3 (en) Oncogenic-ras-signal dependent lethal compounds
WO2007044413A3 (en) Wwox gene, vectors containing the same, and uses in treatment of cancer
WO2008070666A3 (en) Compositions and methods to treat cancer with cpg rich dna and cupredoxins
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
PL2026803T3 (pl) Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2007149798A3 (en) Biomarkers for the progression of alzheimer's disease
WO2007095185A3 (en) Variants in complement regulatory genes predict age-related macular degeneration
EP2134863A4 (en) GENETIC MODIFICATIONS ON CHROMOSOME 16 AND METHODS OF USING THE SAME FOR THE DIAGNOSIS AND TREATMENT OF TYPE I DIABETES
WO2009036100A8 (en) Prediction of qt prolongation based on snp genotype
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
WO2007120955A3 (en) Genes affecting human memory performance
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2007063405A3 (en) Diagnosis and treatment of exocrine pancreatic dysfunction and diabetes using human cel gene
WO2010008858A8 (en) Use of iron-related pathways and genes for treatment and diagnosis of parkinson's disease
WO2008081447A3 (en) Compounds and methods for detection of cells

Legal Events

Date Code Title Description
FG Grant or registration